Edgewise Therapeutics Inc (EWTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Edgewise Therapeutics Inc (EWTX) Competitors
The companies most similar to Edgewise Therapeutics are Viridian Therapeutics (VRDN), Dyne Therapeutics (DYN) and Cogent Biosciences (COGT). By market cap, Edgewise Therapeutics ranks 5th of the 13 companies on this page; TG Therapeutics (TGTX) is the largest at $9.75B.
Peer Comparison
EWTX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics (EWTX) | $5.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Viridian Therapeutics Inc (VRDN) | $3.51B | N/A | 128.5x | 0.0% | -41.8% | -63.5% | 0.00% |
| Dyne Therapeutics Inc (DYN) | $3.22B | N/A | N/A | 0.0% | -42.9% | 0.0% | 0.00% |
| Cogent Biosciences Inc (COGT) | $4.97B | N/A | N/A | 0.0% | -43.4% | -100.0% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Viking Therapeutics Inc (VKTX) | $3.73B | N/A | N/A | 0.0% | -61.0% | 0.0% | 0.00% |
| Disc Medicine Inc. (IRON) | $3.64B | N/A | N/A | 0.0% | -40.0% | 0.0% | 0.00% |
| Crispr Therapeutics AG (CRSP) | $4.10B | N/A | 155.2x | 0.0% | -20.3% | 1325.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Dianthus Therapeutics Inc. (DNTH) | $5.17B | N/A | N/A | 0.0% | N/A | 205.6% | 0.00% |
| Scholar Rock Holding Corp (SRRK) | $5.27B | N/A | N/A | 0.0% | -89.0% | -100.0% | 0.00% |
| Erasca Inc (ERAS) | $5.50B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $3.91B | 176.8x | 15.0x | 0.0% | -41.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Edgewise Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Viridian Therapeutics Inc (VRDN) | Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. | VRDN competitors |
| Dyne Therapeutics Inc (DYN) | Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases... | DYN competitors |
| Cogent Biosciences Inc (COGT) | Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. | COGT competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Viking Therapeutics Inc (VKTX) | Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. | VKTX competitors |
| Disc Medicine Inc. (IRON) | Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development... | IRON competitors |
| Crispr Therapeutics AG (CRSP) | CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. | CRSP competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Dianthus Therapeutics Inc. (DNTH) | Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops... | DNTH competitors |
| Scholar Rock Holding Corp (SRRK) | Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious... | SRRK competitors |
| Erasca Inc (ERAS) | Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers... | ERAS competitors |
Frequently Asked Questions About EWTX
Who are Edgewise Therapeutics' main competitors?
The companies most similar to Edgewise Therapeutics include Viridian Therapeutics (VRDN), Dyne Therapeutics (DYN), Cogent Biosciences (COGT), TG Therapeutics (TGTX) and Viking Therapeutics (VKTX), listed from the closest match.
Who is Edgewise Therapeutics' biggest competitor?
TG Therapeutics (TGTX) is the largest of the similar companies at $9.75B; Viridian Therapeutics (VRDN) is the closest match by business profile, size, sector and industry.
How does EWTX stock compare with its competitors?
EWTX's net margin is 0.0% against a peer median of 0.0%.
Which of Edgewise Therapeutics' competitors pays a higher dividend?
Edgewise Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Edgewise Therapeutics bigger than its competitors?
No. Edgewise Therapeutics is 5th by market cap among the 13 companies on this page; the largest is TG Therapeutics (TGTX) at $9.75B.
EWTX pages: Overview, Earnings, Forecast, Financials, Competitors